Curis to Present at Upcoming Healthcare Conferences in September
| CRIS Stock | USD 1.56 0.01 0.65% |
Slightly above 54% of Curis' investor base is interested to short. The analysis of the overall investor sentiment regarding Curis Inc suggests that many traders are impartial. Curis' investing sentiment can be driven by a variety of factors including economic data, Curis' earnings reports, geopolitical events, and overall market trends.
Curis, Inc. , a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences
Read at finance.yahoo.com
 |
Curis Fundamental Analysis
We analyze Curis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Curis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Curis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Curis is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Curis Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Curis stock to make a market-neutral strategy. Peer analysis of Curis could also be used in its relative valuation, which is a method of valuing Curis by comparing valuation metrics with similar companies.
Peers
Curis Related Equities
| SLRX | Salarius Pharmaceuticals | 8.46 | ||||
| CRVS | Corvus Pharmaceuticals | 4.91 | ||||
| MREO | Mereo BioPharma | 3.03 | ||||
| LXRX | Lexicon Pharmaceuticals | 1.71 | ||||
| AGEN | Agenus | 1.09 | ||||
| RIGL | Rigel Pharmaceuticals | 1.17 |
Additional Tools for Curis Stock Analysis
When running Curis' price analysis, check to measure Curis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curis is operating at the current time. Most of Curis' value examination focuses on studying past and present price action to predict the probability of Curis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curis' price. Additionally, you may evaluate how the addition of Curis to your portfolios can decrease your overall portfolio volatility.